Conflict of Interest Policy
 

The International Journal of Pharma Insight Studies is committed to maintaining the highest standards of publication ethics, transparency, and academic integrity. This Conflict of Interest (COI) Policy aims to ensure that all published content is free from undue influence and bias.

This policy applies to authors, reviewers, editors, and editorial board members involved in the submission, peer-review, and publication process.

A conflict of interest exists when personal, financial, professional, or institutional relationships could influence or be perceived to influence the objectivity of research, peer review, or editorial decision-making.

A Conflict of Interest (COI) arises when secondary interests interfere with, or appear to interfere with, an individual’s primary responsibility toward ethical scholarly publishing.

Conflicts may be financial or non-financial, including but not limited to:

1. Research funding, grants, or sponsorships
2. Employment, consultancies, honoraria, or paid expert testimony
3. Stock ownership, patents, or royalties
4. Personal or professional relationships
5. Academic competition or institutional affiliations
6. Ideological or intellectual beliefs influencing judgment

1. Mandatory Disclosure:
   All authors must disclose any actual or potential conflicts of interest at the time of manuscript submission.

2. Conflict of Interest Statement:
   Each manuscript must include a separate section titled “Conflict of Interest”, clearly stating either:

   • “The authors declare no conflict of interest.”
     OR
     A detailed description of the nature of the conflict.

3. Funding Disclosure:
   All sources of financial support and the role of funding bodies (if any) in study design, data collection, analysis, interpretation, and manuscript preparation must be clearly declared.

4. Accuracy and Transparency:
   Authors are responsible for the completeness and accuracy of all disclosures.

1. Reviewers must disclose any conflicts of interest that may affect their ability to provide an objective and unbiased review.

2. Reviewers should decline the review if:

         (A) They have a close personal or professional relationship with the authors
         (B) They have collaborated with the authors recently
         (C) They have a financial or competitive interest in the research topic

3. All manuscripts received for review must be treated as confidential documents.

1. Editors and editorial board members must disclose any conflicts of interest related to manuscripts under consideration.

2. Editors must not handle manuscripts in which they have:

          (A)Institutional affiliations
          (B)Personal relationships
          (C)Financial or academic interests

3. In such cases, the manuscript will be assigned to an independent and impartial editor.

4. Editorial decisions are based solely on the manuscript’s academic merit, originality, clarity, and relevance.

1. All disclosed conflicts are evaluated by the editorial office on a case-by-case basis.

2. Declared conflicts may be published alongside the article to maintain transparency.

3. If an undisclosed conflict is discovered after publication, the journal may take appropriate action, including:

          (A)Publishing a correction or erratum
          (B)Issuing an expression of concern
          (C)Retraction of the article in serious cases

Failure to disclose relevant conflicts of interest may result in:

1. Rejection of the manuscript
2. Withdrawal or retraction of a published article
3. Notification to authors’ affiliated institutions or funding agencies

Such actions will be taken in accordance with international publication ethics guidelines.

The International Journal of Pharma Insight Studies follows internationally accepted ethical standards, including:

1. Scopus Publication Ethics and Malpractice Guidelines
2. COPE (Committee on Publication Ethics) Principles
3. ICMJE Recommendations for Disclosure of Competing Interests
4. Principles of Transparency and Best Practice in Scholarly Publishing

This Conflict of Interest Policy is reviewed periodically and updated as necessary to remain aligned with global best practices and indexing requirements.